GO
Loading...

Forest Laboratories Inc

More

  • Futures Add to Losses After Citi Earnings Tuesday, 19 Jan 2010 | 7:38 AM ET

    Wall Street investors returned from a long weekend undecided about how to trade, with stock index futures pointing to little change at the open. But earnings from Citigroup could dictate direction from the opening bell.

  • Earnings Roundup: Jan. 19 Friday, 15 Jan 2010 | 4:33 PM ET

    What follows is a roundup of corporate earnings reports for Tuesday, Jan.  19.

  • Farrell: Getting Psyched for the Jobs Report Thursday, 7 Jan 2010 | 9:46 AM ET

    The Bureau of Labor Statistics doesn't release its official jobs report until Friday but there is lots of preamble.

  • Time to Put Money to Work: Stock Pickers Friday, 29 May 2009 | 6:55 PM ET

    We are putting cash back to work, said Ron Muhlenkamp, portfolio manager at The Muhlenkamp Fund, and Jeff Mortimer, CIO of Charles Schwab Investment Management.

  • Earnings Roundup: BK, BLK, USB, STT, & More... Tuesday, 21 Apr 2009 | 11:57 AM ET

    The slumping economy negatively impacted many smaller companies that reported earnings on Tuesday. The following are some firms that reported earnings before the opening bell:

  • Market Insider: Tuesday Look Ahead Monday, 20 Apr 2009 | 9:40 PM ET

    Markets are bracing for a landslide of earnings news Tuesday and more focus on the Treasury's bank bailout plans.

  • Dow Closes Just Shy Of 8000 Thursday, 2 Apr 2009 | 5:21 PM ET

    The Dow rallied for a third day on Thursday, and traded above 8,000 for the first time since early February on an intra-day basis.

  • Options Action: Drug Firm Sees Heavy Call Activity Thursday, 2 Apr 2009 | 1:20 PM ET

    Generic drug company Forest Labs is seeing heavy call activity amid buyout rumors.

  • Biopharma's Ma & Pa Wednesday, 4 Mar 2009 | 11:52 AM ET

    Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."

  • Game Plan: Four Hopeful Signs for Market Friday, 23 Jan 2009 | 6:52 PM ET

    Movement in a few key sectors could give stocks a much-needed boost.

  • Analysts Explained Friday, 23 Jan 2009 | 2:25 PM ET

    Ever wonder how these people decide which stock's a buy and which is a sell? Now you know.

  • Forest Labs: Buy or Sell? Thursday, 22 Jan 2009 | 7:53 PM ET

    Depends on which analyst you believe. Find out who Cramer's siding with.

  • Pops & Drops: Staples, Honda... Wednesday, 3 Sep 2008 | 6:35 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Staples and Honda popped while Nokia and ConAgra dropped.

  • Prescriptions for Your Portfolio Wednesday, 20 Aug 2008 | 12:45 PM ET

    Scott Richter, portfolio manager of the Fifth Third Disciplined Fund, prescribes two stocks in the pharmaceuticals sector.

  • Best Trades Now: Retail, Financials, Pharma & More Monday, 28 Jul 2008 | 4:24 PM ET

    To give investors an edge, CNBC asked the market experts for their best trades now.

  • 4-Star Pharma, Cable Stocks Monday, 28 Jul 2008 | 4:18 PM ET

    Mary Jane Matts knows a few things about "up" stocks in a "down" market, and she's sharing a couple of suggestions with CNBC.

  • Market Insider: Wednesday Look Ahead Tuesday, 8 Jul 2008 | 8:02 PM ET

    The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.

  • Pops & Drops: Valero, Lehman... Friday, 18 Apr 2008 | 6:47 PM ET

    Following are the week’s biggest winners and losers. Find out why shares of Valero and Lehman popped while State Street and Wynn dropped.

  • Pops & Drops: Smithfield Foods, Las Vegas Sands... Tuesday, 15 Apr 2008 | 6:29 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Smithfield Foods and Compuware popped while Manitowoc and Las Vegas Sands dropped.

  • Forest Labs Profit Beats, But Outlook Sluggish Tuesday, 15 Apr 2008 | 9:33 AM ET

    Forest Laboratories on Tuesday posted a better-than-expected profit, but shares fell 7.5 percent as the mid-sized drugmaker projected only slightly higher full-year earnings due to expenses to improve its product line.